I-Mab (NASDAQ:NBP) Downgraded by Wall Street Zen to "Sell"

Key Points

• Wall Street Zen downgraded I-Mab from “Hold” to “Sell,” while the broader analyst consensus remains “Hold” with a $9.00 price target.
• I-Mab shares opened at $1.84, near the lower end of their 52-week range of $1.46 to $6.79. The company reported a quarterly loss of $0.16 per share and analysts expect a full-year loss of $0.30 per share.
• Institutional investors own 38.38% of I-Mab, and Brooklyn Investment Group recently purchased 12,715 shares worth approximately $51,000.

I-Mab (NASDAQ:NBP - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Sunday.

Several other analysts have also recently commented on NBP. HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of I-Mab in a research note on Thursday, August 20th. Weiss Ratings upgraded shares of I-Mab from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, June 1st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $9.00.

I-Mab Price Performance

Shares of I-Mab stock opened at $1.84 on Friday. I-Mab has a 52-week low of $1.46 and a 52-week high of $6.79. The stock has a 50-day simple moving average of $1.82 and a 200-day simple moving average of $2.24. The firm has a market cap of $212.80 million, a price-to-earnings ratio of -5.11 and a beta of 1.47.

I-Mab (NASDAQ:NBP - Get Free Report) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) earnings per share for the quarter. As a group, equities research analysts predict that I-Mab will post -0.3 earnings per share for the current year.

Institutional Trading of I-Mab

An institutional investor recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new stake in I-Mab (NASDAQ:NBP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,715 shares of the company's stock, valued at approximately $51,000. Institutional investors and hedge funds own 38.38% of the company's stock.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source